After an unsuccessful $3.5 billion hostile takeover attempt, Astellas Pharma Inc. raised its acquisition offer for OSI Pharmaceuticals Inc. to $4 billion, and OSI agreed to a friendly buyout. (BioWorld Today)
A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying.
The FDA denied Teva Pharmaceuticals Inc.'s latest attempt to block generic competition to Copaxone (glatiramer acetate) - but hurdles remain for generic Copaxone maker Momenta Pharmaceuticals Inc. (BioWorld Today)
CHICAGO - Between the panels, the presentations and the partnering meetings, days spent at the BIO 2010 annual convention can feel pretty long. But the nights are longer. (BioWorld Today - 2010 BIO)
CHICAGO - Beneath the surface of the BIO 2010 conference, away from the panel sessions, the company presentations, the keynote lunches and the bustling exhibit hall, there's an inner circle of activity - one in which C-level biotech execs race between meetings with potential partners, investors, service providers and other industry players. (BioWorld Today - 2010 BIO)
Dendreon Corp. made history last week by securing approval for Provenge (sipuleucel-T), the first therapeutic cancer vaccine ever cleared by the FDA. (BioWorld Today)
